Quantcast

Latest Chemotherapy regimens Stories

2008-09-09 15:00:09

By HELEN PUTTICK HEALTH CORRESPONDENT DRUGS to help battle cancer were approved for use by the NHS in Scotland yesterday. The Scottish Medicines Consortium (SMC), which advises health boards on the latest treatments, backed the prescription of medicines for patients with lung cancer, leukaemia and lymphoma, which affects the immune system. Doctors welcomed the decision to support use of a treatment, MabThera, in more people with nonHodgkin lymphoma, the sixth-most common cancer. Dr...

2008-08-26 09:00:28

Aveo Pharmaceuticals has started another Phase Ib clinical study for its lead product candidate, the triple VEGF receptor inhibitor AV-951. This open-label, sequential dose escalation study will be conducted at cancer institutions in Europe and will evaluate AV-951 in combination with the Folfox6 chemotherapy regimen in patients with advanced colorectal cancer and other gastrointestinal cancers. This Phase Ib combination therapy trial is designed to determine the safety, tolerability and...

2008-08-12 12:05:00

A Japanese-led study suggests an experimental combination of chemotherapy agents might be a good alternative to standard lung cancer treatment. In the phase II multicenter study of 56 patients with advanced small cell lung cancer, scientists said response rate, progression-free survival and overall survival from a combination of S-1 and irinotecan were similar to, or better than, those reported from standard treatment with platinum-based chemotherapy regimens. "There continues to be...

2008-08-05 03:00:11

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the "Company") (Nasdaq: CTIC; MTA) t announced that Craig W. Philips has assumed his role as CTI's new President, and will concentrate on managing the company's drug development and commercial operations. Most recently, Philips was Vice President and General Manager of Bayer Healthcare Oncology. He will report to CTI's James A. Bianco, M.D., who has served as President and Chief Executive Officer since its founding and will...

2008-06-24 02:29:21

BETHLEHEM, Pa., June 23 /PRNewswire/ -- A new blood test may make it easier for oncologists to accurately measure and personalize 5-fluorouracil (5-FU) dosing for patients undergoing continuous infusion chemotherapy regimens. Data from a multicenter trial showed that a nanoparticle-based immunoassay from Saladax Biomedical, called 5-FU Personalized Chemotherapy Management (PCM(R)), performed as well as high performance liquid chromatography (HPLC) or LC-MS/MS, but was easier to use, more...

3d0bf4b0545085611d5bdef00123cc721
2008-03-19 08:30:00

Researchers from the Indiana University School of Medicine and the Purdue School of Science at Indiana University-Purdue University Indianapolis have created the first three-dimensional image of how a well-established chemotherapy agent targets and binds to DNA. The study, which publishes online the week of March 17 in the Early Edition of the Proceedings of the National Academy of Sciences, may help scientists develop better chemotherapy drugs to treat a wide range of cancers.Using X-ray...

2006-12-09 12:00:12

ORLANDO, Fla., Dec. 9 /PRNewswire/ -- Chemotherapy, the most common type of treatment for cancer patients, can cause troublesome side effects, such as nausea and vomiting, hair loss, fatigue, and life-threatening toxicities. An important area of progress has been the development of minimally toxic non- chemotherapy agents that add to the effectiveness of chemotherapy. Three studies being presented today at the 48th Annual Meeting of the American Society of Hematology (ASH(TM)) highlight...

2005-12-08 10:45:21

LOS ANGELES (Reuters) - The breast cancer drug Herceptin, shown recently to improve survival in women with early-stage breast cancer, carries with it a risk of heart damage, but a chemotherapy regimen can limit the danger, researchers said on Thursday. Genentech Inc.'s Herceptin has been on the market since 1998 as a treatment for the 25 percent to 30 percent of breast cancer patients, who have tumors that generate a protein called HER-2 and whose cancer has spread beyond the...

2005-10-20 14:32:58

New treatment advances for patients with follicular lymphoma, previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center. Scientists compared outcomes for 960 patients treated with...

2005-06-20 16:50:00

When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment. In a new study, researchers from the University of Bologna, Italy, demonstrate that Thal-Dex (thalidomide used in combination with dexamethasone) is more powerful than conventional chemotherapy for the treatment of multiple myeloma. Their findings will be published in the July 1, 2005, issue of Blood, the official journal of...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related